PDS Biotechnology
PDSB
52 hedge funds and large institutions have $137M invested in PDS Biotechnology in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 4 closing their positions.
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
27% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 15
0.07% more ownership
Funds ownership: 2.52% → 2.58% (+0.07%)
0% more funds holding
Funds holding: 52 → 52 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
25% less capital invested
Capital invested by funds: $182M → $137M (-$45.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.26M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$3.08M |
| 3 |
RC
RegentAtlantic Capital
Morristown,
New Jersey
|
+$1.34M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$1.09M |
| 5 |
Millennium Management
New York
|
+$754K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.56M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$475K |
| 3 |
Goldman Sachs
New York
|
-$361K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$328K |
| 5 |
Morgan Stanley
New York
|
-$261K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Barclays
London,
United Kingdom
| $1K | -$3.17K | -16 | -80% |
|
52
BNP Paribas Financial Markets
Paris,
France
| $747 | -$8.12K | -41 | -91% |
|
|
53
Goldman Sachs
New York
| – | -$361K | -1,445 | Closed |
|
|
54
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$328K | -1,312 | Closed |
|
55
LPL Financial
San Diego,
California
| – | -$162K | -634 | Closed |
|
|
TRCT
56
Tower Research Capital (TRC)
New York
| – | -$1K | -3 | Closed |
|
PDSB Hedge Fund Activity: Q1 2017 in Review
52 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q1 2017, worth a combined $137M — down 25% from $182M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PDSB positions and 4 closed out — a net gain of 5 holders — while 19 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $7.26M. The largest seller was Fidelity Investments, cutting an estimated $1.56M.
- 52 institutional investors held PDS Biotechnology (PDSB) as of Q1 2017, unchanged from Q4 2016.
- Funds reported $137M of PDS Biotechnology stock for Q1 2017, down 25% quarter-over-quarter.
- 9 funds opened new PDS Biotechnology positions in Q1 2017 and 4 closed out, a net change of +5 holders.
- The largest PDS Biotechnology buyer in Q1 2017 was BlackRock, an estimated $7.26M added.
- The largest PDS Biotechnology seller in Q1 2017 was Fidelity Investments, an estimated $1.56M sold.
Based on aggregated 13F filings for Q1 2017.